FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950536465> ?p ?o ?g. }

• W2950536465 endingPage "406" @default.
• W2950536465 startingPage "396" @default.
• W2950536465 abstract "<h2>Summary</h2><h3>Background</h3> Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality. Veverimer, a non-absorbed, counterion-free, polymeric drug candidate selectively binds and removes hydrochloric acid from the gastrointestinal lumen. <h3>Methods</h3> We did a multicentre, randomised, blinded, placebo-controlled, 40-week extension of a 12-week parent study at 29 sites (hospitals and specialty clinics) in seven countries (Bulgaria, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA). Eligible patients were those with chronic kidney disease (estimated glomerular filtration rate 20–40 mL/min per 1·73 m²) and metabolic acidosis (serum bicarbonate 12–20 mmol/L), who had completed the 12-week parent study, for which they were randomly assigned (4:3) to veverimer (6 g/day) or placebo as oral suspensions in water with food. Participants in the extension continued with the same treatment assignment as in the parent study. The primary endpoint was safety; the four secondary endpoints assessed the long-term effects of veverimer on serum bicarbonate concentration and physical functioning. The safety analysis set was defined as all patients who received any amount of study drug. This trial is registered at ClinicalTrials.gov, number NCT03390842, and has now completed. <h3>Findings</h3> Participants entered the study between Dec 20, 2017, and May 4, 2018. Of the 217 patients randomly assigned to treatment in the parent study (124 to veverimer and 93 to placebo), 196 patients (114 veverimer and 82 placebo) continued on their blinded randomised treatment assignment into this 40-week extension study. Compared with placebo, fewer patients on veverimer discontinued treatment prematurely (3% <i>vs</i> 10%, respectively), and no patients on veverimer discontinued because of an adverse event. Serious adverse events occurred in 2% of veverimer-treated patients and in 5% of placebo patients (two of whom died). Renal system adverse events were reported in 8% and 15% in the veverimer and placebo groups, respectively. More patients on veverimer than placebo had an increase in bicarbonate (≥4 mmol/L or normalisation) at week 52 (63% <i>vs</i> 38%, p=0·0015) and higher bicarbonate concentrations were observed with veverimer than placebo at all timepoints starting at week 1 (p<0·001). Veverimer resulted in improved patient-reported physical functioning (Kidney Disease and Quality of Life–Physical Function Domain) versus placebo with a mean placebo-subtracted change at end of treatment of 12·1 points (SE 3·3; p<0·0001). Time to do the repeat chair stand test improved by 4·3 s (1·2) on veverimer versus 1·4 s (1·2) on placebo (p<0·0001). <h3>Interpretation</h3> In patients with chronic kidney disease and metabolic acidosis, veverimer safely and effectively corrected metabolic acidosis and improved subjective and objective measures of physical function. <h3>Funding</h3> Tricida." @default.
• W2950536465 created "2019-06-27" @default.
• W2950536465 creator A5010386833 @default.
• W2950536465 creator A5019935894 @default.
• W2950536465 creator A5042762794 @default.
• W2950536465 creator A5056005655 @default.
• W2950536465 creator A5058965585 @default.
• W2950536465 creator A5076583644 @default.
• W2950536465 creator A5089363439 @default.
• W2950536465 creator A5091483213 @default.
• W2950536465 date "2019-08-01" @default.
• W2950536465 modified "2023-09-27" @default.
• W2950536465 title "Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension" @default.
• W2950536465 cites W1983659087 @default.
• W2950536465 cites W1994174181 @default.
• W2950536465 cites W2001920176 @default.
• W2950536465 cites W2010550213 @default.
• W2950536465 cites W2014046186 @default.
• W2950536465 cites W2019183501 @default.
• W2950536465 cites W2026719046 @default.
• W2950536465 cites W2040225557 @default.
• W2950536465 cites W2042680317 @default.
• W2950536465 cites W2054323843 @default.
• W2950536465 cites W2060886633 @default.
• W2950536465 cites W2085538515 @default.
• W2950536465 cites W2101690764 @default.
• W2950536465 cites W2108629029 @default.
• W2950536465 cites W2114579663 @default.
• W2950536465 cites W2117650285 @default.
• W2950536465 cites W2122705341 @default.
• W2950536465 cites W2157610609 @default.
• W2950536465 cites W2157645770 @default.
• W2950536465 cites W2159595769 @default.
• W2950536465 cites W2277103284 @default.
• W2950536465 cites W2535533723 @default.
• W2950536465 cites W2761903250 @default.
• W2950536465 cites W2765955869 @default.
• W2950536465 cites W2883838722 @default.
• W2950536465 cites W2902701987 @default.
• W2950536465 cites W2920797532 @default.
• W2950536465 cites W3026731266 @default.
• W2950536465 doi "https://doi.org/10.1016/s0140-6736(19)31388-1" @default.
• W2950536465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31248662" @default.
• W2950536465 hasPublicationYear "2019" @default.
• W2950536465 type Work @default.
• W2950536465 sameAs 2950536465 @default.
• W2950536465 citedByCount "67" @default.
• W2950536465 countsByYear W29505364652019 @default.
• W2950536465 countsByYear W29505364652020 @default.
• W2950536465 countsByYear W29505364652021 @default.
• W2950536465 countsByYear W29505364652022 @default.
• W2950536465 countsByYear W29505364652023 @default.
• W2950536465 crossrefType "journal-article" @default.
• W2950536465 hasAuthorship W2950536465A5010386833 @default.
• W2950536465 hasAuthorship W2950536465A5019935894 @default.
• W2950536465 hasAuthorship W2950536465A5042762794 @default.
• W2950536465 hasAuthorship W2950536465A5056005655 @default.
• W2950536465 hasAuthorship W2950536465A5058965585 @default.
• W2950536465 hasAuthorship W2950536465A5076583644 @default.
• W2950536465 hasAuthorship W2950536465A5089363439 @default.
• W2950536465 hasAuthorship W2950536465A5091483213 @default.
• W2950536465 hasConcept C126322002 @default.
• W2950536465 hasConcept C142724271 @default.
• W2950536465 hasConcept C159641895 @default.
• W2950536465 hasConcept C168563851 @default.
• W2950536465 hasConcept C197934379 @default.
• W2950536465 hasConcept C203092338 @default.
• W2950536465 hasConcept C204787440 @default.
• W2950536465 hasConcept C27081682 @default.
• W2950536465 hasConcept C2778653478 @default.
• W2950536465 hasConcept C2779246250 @default.
• W2950536465 hasConcept C2779403450 @default.
• W2950536465 hasConcept C71924100 @default.
• W2950536465 hasConcept C90924648 @default.
• W2950536465 hasConceptScore W2950536465C126322002 @default.
• W2950536465 hasConceptScore W2950536465C142724271 @default.
• W2950536465 hasConceptScore W2950536465C159641895 @default.
• W2950536465 hasConceptScore W2950536465C168563851 @default.
• W2950536465 hasConceptScore W2950536465C197934379 @default.
• W2950536465 hasConceptScore W2950536465C203092338 @default.
• W2950536465 hasConceptScore W2950536465C204787440 @default.
• W2950536465 hasConceptScore W2950536465C27081682 @default.
• W2950536465 hasConceptScore W2950536465C2778653478 @default.
• W2950536465 hasConceptScore W2950536465C2779246250 @default.
• W2950536465 hasConceptScore W2950536465C2779403450 @default.
• W2950536465 hasConceptScore W2950536465C71924100 @default.
• W2950536465 hasConceptScore W2950536465C90924648 @default.
• W2950536465 hasIssue "10196" @default.
• W2950536465 hasLocation W29505364651 @default.
• W2950536465 hasOpenAccess W2950536465 @default.
• W2950536465 hasPrimaryLocation W29505364651 @default.
• W2950536465 hasRelatedWork W2493681650 @default.
• W2950536465 hasRelatedWork W2766008196 @default.
• W2950536465 hasRelatedWork W2913679435 @default.
• W2950536465 hasRelatedWork W3007053288 @default.
• W2950536465 hasRelatedWork W3048332889 @default.
• W2950536465 hasRelatedWork W3125174675 @default.
• W2950536465 hasRelatedWork W3172359983 @default.

• next